Perrigo Company (NYSE:PRGO) EVP John Wesolowski bought 700 shares of the stock in a transaction that occurred on Thursday, December 14th. The shares were purchased at an average price of $85.80 per share, with a total value of $60,060.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
John Wesolowski also recently made the following trade(s):
- On Thursday, December 7th, John Wesolowski sold 450 shares of Perrigo stock. The shares were sold at an average price of $83.09, for a total value of $37,390.50.
- On Wednesday, November 29th, John Wesolowski sold 388 shares of Perrigo stock. The shares were sold at an average price of $87.20, for a total value of $33,833.60.
Shares of Perrigo Company (PRGO) traded down $0.19 during midday trading on Friday, hitting $91.80. The stock had a trading volume of 559,679 shares, compared to its average volume of 1,007,144. The company has a quick ratio of 1.24, a current ratio of 1.72 and a debt-to-equity ratio of 0.54. Perrigo Company has a 1-year low of $63.68 and a 1-year high of $92.75. The firm has a market cap of $12,960.00, a price-to-earnings ratio of -10.02, a PEG ratio of 1.92 and a beta of 0.64.
Perrigo (NYSE:PRGO) last issued its earnings results on Thursday, November 9th. The company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.28. Perrigo had a positive return on equity of 11.60% and a negative net margin of 26.28%. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the company earned $1.65 EPS. The business’s quarterly revenue was down 2.0% on a year-over-year basis. sell-side analysts forecast that Perrigo Company will post 4.88 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 19th. Stockholders of record on Friday, December 1st were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend was Thursday, November 30th. Perrigo’s dividend payout ratio (DPR) is presently -6.99%.
A number of equities analysts recently commented on the company. Cantor Fitzgerald set a $107.00 target price on Perrigo and gave the company a “buy” rating in a report on Friday. BidaskClub upgraded Perrigo from a “sell” rating to a “hold” rating in a research note on Saturday, September 16th. Leerink Swann started coverage on Perrigo in a research note on Tuesday, January 2nd. They issued a “market perform” rating and a $90.00 price objective for the company. Morgan Stanley lifted their price objective on Perrigo from $79.00 to $92.00 and gave the company an “equal weight” rating in a research note on Friday, November 10th. Finally, Jefferies Group reiterated a “hold” rating and issued a $81.00 price objective on shares of Perrigo in a research note on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $92.00.
Hedge funds and other institutional investors have recently modified their holdings of the company. Commonwealth Bank of Australia raised its position in shares of Perrigo by 13.8% during the 2nd quarter. Commonwealth Bank of Australia now owns 1,455 shares of the company’s stock worth $108,000 after acquiring an additional 176 shares in the last quarter. Bessemer Group Inc. increased its position in Perrigo by 1,046.2% during the second quarter. Bessemer Group Inc. now owns 2,235 shares of the company’s stock worth $169,000 after buying an additional 2,040 shares during the period. Allianz Asset Management GmbH acquired a new position in Perrigo during the third quarter worth approximately $217,000. Conning Inc. acquired a new position in Perrigo during the third quarter worth approximately $219,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in Perrigo during the third quarter worth approximately $222,000. 83.29% of the stock is currently owned by institutional investors and hedge funds.
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.